Marshall University launches latest clinical trial cohort for non-opioid treatment of neonatal ...
A clinical trial at Marshall University and Marshall Health Network evaluates the safety and efficacy of oral lofexidine, a non-opioid medication, for newborns with neonatal opioid withdrawal syndrome (NOWS) due to prenatal opioid exposure. The study, sponsored by USWM, LLC through a grant from NIDA, aims to provide a non-opioid treatment option and is ongoing with enrollment targeted to be completed by the end of 2024.
Related Clinical Trials
Highlighted Terms
Related News
A clinical trial at Marshall University and Marshall Health Network evaluates the safety and efficacy of oral lofexidine, a non-opioid medication, for newborns with neonatal opioid withdrawal syndrome (NOWS) due to prenatal opioid exposure. The study, sponsored by USWM, LLC through a grant from NIDA, aims to provide a non-opioid treatment option and is ongoing with enrollment targeted to be completed by the end of 2024.